Company news
Atrium Therapeutics, Inc. news in 2023
Atrium Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.
Avidity Biosciences Reports Positive Data Demonstrating AOC 1044 Delivers Unprecedented Concentrations of PMO in Muscle Following a Single Dose in Healthy Volunteers from Phase 1/2 EXPLORE44™ Trial for Duchenne Muscular Dystrophy
December 12, 2023
Avidity Biosciences Announces Expansion of Cardiovascular Collaboration with Bristol Myers Squibb for up to Five Targets Utilizing Avidity's Proprietary AOC™ Platform Technology
November 27, 2023
Avidity Biosciences Reports Third Quarter 2023 Financial Results and Recent Highlights
November 7, 2023
Avidity Biosciences Announces New Positive AOC 1001 Data Demonstrating Improvement in Multiple Additional Functional Endpoints and Favorable Long-term Safety and Tolerability in People with Myotonic Dystrophy Type 1
October 6, 2023
Avidity Biosciences Announces Upcoming Presentations at 28th Annual Congress of the World Muscle Society
September 25, 2023
Avidity Biosciences Joins with Patient Communities to Raise Awareness During National Muscular Dystrophy Awareness Month as it Advances Three Muscular Dystrophy Clinical Programs
September 6, 2023
Avidity Biosciences Announces Upcoming Presentations at 2023 Myotonic Dystrophy Foundation Annual Conference
August 30, 2023
Avidity Biosciences Receives FDA Orphan Drug Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 Skipping
August 14, 2023
Avidity Biosciences Reports Second Quarter 2023 Financial Results and Recent Highlights
August 7, 2023
Avidity Biosciences Joins with Patients, Caregivers and Healthcare Providers Globally to Support World Facioscapulohumeral Muscular Dystrophy (FSHD) Day
June 19, 2023
Avidity Biosciences Announces Upcoming Presentations at the 30th Annual FSHD Society International Research Congress
June 7, 2023
Avidity Biosciences Announces FDA Eases Partial Clinical Hold on AOC 1001 Providing a Clear Path Forward to Finalize Pivotal Dose and Phase 3 Design in Adults with Myotonic Dystrophy Type 1
May 16, 2023
Avidity Biosciences Reports First Quarter 2023 Financial Results and Recent Highlights
May 8, 2023
Avidity Biosciences Announces Positive Topline Data from AOC 1001 Phase 1/2 MARINA™ Trial Demonstrating Functional Improvement, Disease Modification and Favorable Safety and Tolerability Profile in People Living with Myotonic Dystrophy Type 1
April 26, 2023
Avidity Biosciences Granted FDA Fast Track Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy Mutations Amenable to Exon 44 Skipping
April 23, 2023
Avidity Biosciences Announces Upcoming Presentations at the 75th American Academy of Neurology Annual Meeting
April 16, 2023
Avidity Biosciences to Host Investor and Analyst Event Focused on AOC 1001 Topline Data from Phase 1/2 MARINA™ Trial on April 27, 2023
April 12, 2023
Avidity Biosciences Provides Regulatory Update on AOC 1001 for Myotonic Dystrophy Type 1 and Plans to Present Top-line Data from Phase 1/2 MARINA™ Trial at AAN Annual Meeting
March 29, 2023
Avidity Biosciences Announces Upcoming Presentations at 2023 MDA Clinical & Scientific Conference
March 12, 2023
Avidity Biosciences Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Highlights
February 27, 2023
Avidity Advances RNA Programs and Expands into New Therapeutic Areas Utilizing its AOC™ Platform
February 26, 2023
Avidity Biosciences Announces Arthur A. Levin to Join Board of Directors and Transition to Distinguished Scientist and Strategic Leader
February 22, 2023
Avidity Biosciences Receives FDA Orphan Drug Designation for AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy
February 13, 2023
Avidity Biosciences Granted FDA Fast Track Designation for AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy
January 17, 2023